Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Merck & Co’s Prometheus deal; Lilly’s US mirikizumab rejection; Moderna and Merck’s mRNA cancer vaccine shows promise; how SeaGen nearly lost its big pharma bidders; and Chinese firms move ahead with potential rivals to Enhertu.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 21 April 2023, including: Merck & Co., Inc.’s Prometheus deal; Eli Lilly and Company’s US mirikizumab rejection; Moderna, Inc. and Merck & Co., Inc.’s mRNA cancer vaccine shows promise; how Seagen Inc. nearly lost its big pharma bidders; and Chinese firms move ahead with potential rivals to Enhertu.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy" - Scrip, 17 Apr, 2023.)
(Also see "Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL" - Scrip, 14 Apr, 2023.)
(Also see "Could Moderna/Merck Cancer Vaccine Succeed Where Others Have Flopped?" - Scrip, 16 Apr, 2023.)
(Also see "Seagen, With Two Big Pharma Bidders, Nearly Lost Both" - Scrip, 17 Apr, 2023.)
(Also see "AACR: Chinese Pharma Firms Showcase Enhertu Fast-Followers" - Scrip, 18 Apr, 2023.)